Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection

Annals of Pharmacotherapy

Volumn 41, Issue 5, 2007, Pages 880-884

  Paredes, Angelo H ^a   Lewis, James H ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic hepatitis B; Drug induced autoimmune hepatite; Terbinafine

Indexed keywords

ADEFOVIR; DIURETIC AGENT; TERBINAFINE; VITAMIN K GROUP;

ADULT; ANOREXIA; ARTICLE; ASCITES; AUTOIMMUNE HEPATITIS; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; MALAISE; MALE; ONYCHOMYCOSIS; PRIORITY JOURNAL; SIDE EFFECT; TAIWAN; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

ALANINE TRANSAMINASE; ANTIFUNGAL AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; FOOT DERMATOSES; HEPATITIS B, CHRONIC; HEPATITIS, AUTOIMMUNE; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; ONYCHOMYCOSIS;

EID: 34248530538     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H400     Document Type: Article

References (23)

1. Ryder NS, Dupont MC. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of the fungal and mammalian enzymes. Biochem J 1985;230:765-70.
2. Gupta AK, del Rosso JQ, Lynde CW, Brown GH, Shear NH. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol 1998;23:64-7. DOI 10.1046/j.1365-2230.1998.00321.x
3. Bess AL, Cunningham S. Dear doctor letter re: Lamisil (terbinafine HCl) tablets for patients with preexisting liver disease. East Hanover, NJ: Novartis Pharmaceuticals Corp, May 2001. www.fda.gov/medwatch/SAFETY/2001/ Lamisil_deardoc.pdf (accessed 2006 Mar 5).
4. Ajit C, Suvannasankha A, Zaen N, Munoz SJ. Terbinafine-associated hepatotoxicity. Am J Med Sci 2003;325:292-5. DOI 10.1097/00000441-200305000- 00008
5. Agarwal K, Manas D, Hudson M. Terbinafine and fulminant hepatic failure. N Engl J Med 1999;340:1292-3. DOI 10.1056/NEJM199904223401617
6. Mallat A, Zafrani ES, Metreau JM, Dhumeaux D. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci 1997;42:1486-8. DOI 10.1023/A:1018870828038
7. Conjeevaram G, Vongthavaravat V, Sumner R, Koff RS. Terbinafine-induced hepatitis and pancytopenia. Dig Dis Sci 2001;46:1714-6. DOI 10.1023/A: 1010657605476
8. Walter RB, Lukaschek J, Renner EL, Mullhaupt B, Bachli EB. Fatal hepatic veno-occlusive disease associated with terbinafine in a liver transplant recipient. J Hepatol 2003;38:373-4. DOI 10.1016/S0168-8278(02)00411-7
9. Lewis JH, Zimmerman HJ. Drug-induced autoimmune liver disease. In: Krawitt EL, Wiesner RH, Nishioka M, eds. Autoimmune liver diseases. 2nd ed. Amsterdam: Elsevier, 1998:627-49.
10. Khokhar O, Gange C, Clement S, Lewis J. Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction. Dig Dis Sci 2005;50:2007-11. Epub 22 Feb 2005. DOI 10.1007/s10620-005-1302-0
11. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Am J Epidemiol 2001;154:193-206. Epub 4 Apr 2001. DOI 10.1093/aje/154.3.193
12. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102:2108-13.
13. Cohen C, Berson SD, Shulman G, Budgeon LR. Liver iron stores and hepatitis B antigen status. Cancer 1985;56:2201-4. Epub 29 Jun 2005.
14. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004; 99:860-5. Epub 27 Apr 2004. DOI 10.1111/j.1572-0241.2004.04152.x
15. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986;6:133-7.
16. Lok ASF, Lai CL. Acute exacerbation in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990;10:29-34. DOI 10.1016/0168-8278(90)90069-4
17. Manegold C, Hannoun C, Wywiol A, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001;32:144-8. Epub 13 Dec 2000. DOI 10.1086/317535
18. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201-6. Epub 30 Dec 2003. DOI 10.1002/hep.510310129
19. Mackay IR. The immunological mediation of drug reactions affecting the liver. In: Farrell GC, ed. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994:61-82.
20. Iverson SL, Uetrecht JP. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem Res Toxicol 2001;14:175-81. Epub 16 Jan 2001. DOI 10.1021/tx0002029
21. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
22. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30. DOI 10.1016/0895-4356(93)90101-6
23. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-6. DOI 10.1016/0895-4356(93)90102-7